Measurement of bone turnover in prostate cancer patients receiving intermittent androgen suppression therapy | Zendy

Hamilton | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Measurement of bone turnover in prostate cancer patients receiving intermittent androgen suppression therapy

Author(s) -

Hamilton

Publication year - 2010

Publication title -

open access journal of urology

Language(s) - English

Resource type - Journals

ISSN - 1179-1551

DOI - 10.2147/oaju.s13046

Subject(s) - prostate cancer , medicine , n terminal telopeptide , bone remodeling , endocrinology , testosterone (patch) , urology , bone mineral , prostate specific antigen , prostate , androgen deprivation therapy , osteoporosis , cancer , androgen , hormone , osteocalcin , chemistry , alkaline phosphatase , biochemistry , enzyme

Reports on clinical measurements of bone mineral density (BMD) in prostate cancer patients undergoing intermittent androgen suppression therapy (IAS) that allows for hormonal recovery between treatment cycles indicate decreased osteoporosis compared to continuous androgen suppression therapy (CAS). In the present study the effect of IAS on bone metabolism by determinations of CrossLaps, a biochemical marker of collagen degradation, were examined.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research